Eli Lilly & Co. (LLY) to Charge $2,100 Per Dose of Bebtelovimab Antibody Drug - WSJ
Tweet
Share
E-mail
Get Alerts LLY Hot Sheet
Price: $1,107.08 --0%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.6%
Revenue Growth %: +31.7%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.6%
Revenue Growth %: +31.7%
Join SI Premium – FREE
Lilly (NYSE: LLY) to Charge List Price of $2,100 Per Dose of Bebtelovimab Antibody Drug -- WSJ
- to Start Commercial Distribution of Covid-19 Antibody Treatment Week of Aug. 15
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly plans European weight-loss pill launch by early 2027
- Neuronetics promotes CTO to EVP, General Manager of Greenbrook
- This digital health stock is ready to re-rate higher: Goldman
Create E-mail Alert Related Categories
Corporate News, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
